Research Article
REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
Table 2
Patients’ characteristics at the beginning of ICI-1 and ICI-2 therapies.
| | Characteristics | ICI-1 (N = 45), No. (%) | ICI-2 (N = 45), No. (%) |
| | ECOG performance status | | 0 | 23 (52) | 16 (36) | | 1 | 20 (45) | 18 (41) | | ≥2 | 1 (2) | 10 (23) | | Missing | 1 | 1 |
| | No. of metastatic sites | | 1 | 14 (32) | 8 (18) | | 2 | 15 (34) | 12 (27) | | ≥3 | 15 (34) | 25 (56) | | Missing | 1 | 0 |
| | Metastatic sites | | Lung | 31 (74) | 32 (76) | | Lymph nodes | 20 (48) | 19 (45) | | Liver | 10 (24) | 15 (36) | | Bone | 10 (24) | 13 (31) | | Adrenal gland | 4 (10) | 9 (21) | | Renal | 2 (5) | 6 (14) | | CNS | 4 (10) | 5 (12) | | Other | 13 (31) | 17 (40) | | Missing | 3 | 3 |
| | IMDC score | | Favorable (0) | 12 (29) | 9 (23) | | Intermediate (1-2) | 25 (60) | 10 (25) | | Poor (3–6) | 5 (12) | 21 (53) | | Missing | 3 | 5 |
| | Prior lines of therapy, median (range) | 1 (0–6) | 3 (1–9) |
| | Treatment received | | ICI alone [1] | 37 (82) | 42 (93) | | Nivolumab | 35 (78) | 42 (93) | | Nivolumab-ipilimumab | 5 (11) | 3 (7) | | ICI + TT [2] | 3 (7) | 0 (0) |
| | Radiotherapy during ICI treatment | 5 (11) | 5 (11) | | Missing | 1 | 0 |
| | Systemic corticosteroids use | 7 (17) | 4 (10) | | Missing | 4 | 4 |
| | Ongoing ICI | 0 (0) | 13 (29) | | Discontinuation of ICI | 45 (100) | 32 (71) | | Progression | 22 (49) | 30 (94) | | Toxicity | 12 (27) | 1 (3) | | Clinical decision | 11 (24) | 1 (3) |
| | Treatment received between ICI regimens | | 0 | 19 (42) | | 1 | 17 (38) | | ≥2 | 9 (20) |
|
|
1Two patients received anti-PD-L1 monotherapy: avelumab and atezolizumab. 2Treatments received: avelumab + axitinib, nivolumab + tivozanib, and pembrolizumab + lenvatinib. ICI, immune checkpoint inhibitor; ECOG, Eastern Cooperative Oncology Group; CNS, central nervous system; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; TT, targeted therapy.
|
